• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Johnson & Johnson (JnJ) (Group)

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 121,000 men and women in 57 countries and sell products throughout the world. *

 

	Start	1888-01-01 established?
	Industry	pharmaceutical
	Industry 2	diagnostics (medical/biological)
	Street	One Johnson & Johnson Plaza
	City	08933 New Brunswick, NJ
		Address record changed: 2008-12-07
Basic data	Employees	J: more than 100,0 (2017-01-26)
	Currency	USD
	Annual sales	61,095,000,000 (sales, consolidated (2007) 2007-12-31)
	Profit	10,576,000,000 (2007-12-31)
	Cash	16,055,000,000 (2005-12-31)
		* Document for �About Section�:
		Record changed: 2019-01-24

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] MeiraGTx Holdings plc. (5/14/19). "Press Release: MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....
• [2] Iktos. (4/29/19). "Press Release: Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery". Paris....
• [3] MeiraGTx Holdings plc. (3/26/19). "Press Release: MeiraGTx Reports Full Year 2018 Financial Results". London & New York, NY....
• [4] AdoRx Therapeutics Ltd.. (2/28/19). "Press Release: AdoRx Therapeutics Announces Collaboration With Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics". Edinburgh....
• [5] Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent....
• [6] MorphoSys AG. (2/27/19). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received U.S. FDA Approval for Tremfya One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis". Planegg....
• [7] MeiraGTx Holdings plc. (2/27/19). "Press Release: MeiraGTx Announces $80 Million Private Placement of Ordinary Shares". London & New York, NY....
• [8] MeiraGTx Holdings plc. (1/31/19). "Press Release: MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases". London & New York, NY....
• [9] Genmab A/S. (1/22/19). "Press Release: Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma". Copenhagen....
• [10] Genmab A/S. (1/22/19). "Press Release: Genmab Announces 2018 Net Sales Figures for Darzalex (Daratumumab)". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.